NCT02531191已完成1 期
ASP015K Pharmacokinetic Study - Bioequivalence Evaluation of a Small and Current Tablet of ASP015K
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 主要终点
- Pharmacokinetics (PK) parameter of ASP015K: Area under the concentration-time curve (AUC) from the time of dosing to the time of the last sampling (AUCt)
研究概览
简要总结
The objective of this study is to evaluate the bioequivalence of a new tablet versus a current tablet of ASP015K under fasting conditions after single oral administration in healthy male subjects.
详细描述
This is an open-label, randomized, single dose, 2-way crossover designed study. Forty non-elderly healthy male subjects will receive an ASP015K small tablet or an ASP015K current tablet in each period under fasted conditions. If the bioequivalence between two tablets cannot be demonstrated because of an insufficient number, an add-on subject study will be conducted as needed. The design of the add-on subject study will be the same with that of the initial study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 44 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •50.0 kg ≤ body weight at screening < 80.0 kg
- •17.6 ≤ BMI at screening < 26.4 [BMI = Body weight (kg) / (Body height (m))2]
- •Subjects who agree to use the following highly effective contraception consisting of two forms of birth control (at least one of which must be a barrier method) starting at written informed consent through 90 days after the study drug administration in Period
- •Subjects who agree not to donate sperm starting at informed consent through 90 days after the study drug administration in Period
- •Subjects judged as healthy by investigator or sub-investigator based on physical examinations (subjective symptoms and objective findings) and all clinical tests obtained at screening and from check-in to immediately before the study drug administration in Period 1.
排除标准
- •Subjects who have received investigational drugs within 120 days prior to screening or who plan to receive investigational drugs from screening assessment to check-in in Period 1 (Day -1).
- •Any blood donation or blood drawing apply the following:
- •Whole blood collection (≥ 400 mL): from 90 days prior to screening to check-in in Period 1 (Day -1)
- •Whole blood collection (≥ 200 mL): from 30 days prior to screening to check-in in Period 1 (Day -1)
- •Platelet or plasma donation: from 30 days prior to screening to check-in in Period 1 (Day -1)
- •Subjects who had used or plan to use any prescribed or non-prescribed drugs within 7 days prior to check-in in Period 1 (Day -1).
- •Any deviation of blood pressure, pulse, body temperature, or 12-lead ECG at screening or check-in in Period 1 (Day -1) from the following normal range:
- •Supine pressure: Systolic: ≥ 90 mmHg, ≤ 140 mmHg; Diastolic: ≥ 40 mmHg, ≤ 90 mmHg
- •Supine pulse: ≥ 40 bpm, ≤ 99 bpm
- •Axillary temperature: ≥ 35.0 ºC, ≤ 37.0 ºC
- •12-lead ECG: Normal or clinically irrelevant abnormality QTc interval: ≥ 330 msec, < 430 msec
- •Any deviation of laboratory tests at Screening or on Day -1 (check-in) in Period 1 from the following normal range. Normal range of each test at the test or assay site will be used.
- •Hematology: > 20% of upper limit or < 20% of lower limit.
- •Chemistry: deviation of ALT, AST, Cre, blood electrolytes (Na, K, Cl), or fasting blood glucose. > 20% of upper limit or < 20% of lower limit in other than above tests; however no lower limit is set with respect to ALT, AST, γ-GTP, T-Bil, ALP, LDH, CK, T-Cho, TG, Cre, and UA.
- •Urinalysis (qualitative): deviation in any of the urinalysis.
- •Urinary drug abuse test: positive for benzodiazepines, cocaine-based narcotics, analeptic drugs, cannabis, barbituric acid derivatives, morphine-based narcotics, phencyclidines, or tricyclic antidepressants.
- •Immunological test: positive for HBs antigen, HBc antibody, HCV antibody, HIV antigen or antibody, or syphilis.
- •Subjects who have any history or complication of drug allergies.
- •Subjects who have a history of upper gastrointestinal symptoms, i.e. nausea, vomit, stomach ache, etc. within 7 days prior to check-in in Period 1 (Day -1).
- •Subjects who have any history or complication of hepatic disease, i.e. viral hepatitis, drug induced liver injury, hepatic dysfunction, etc.
- •Subjects who have any history or complication of cardiac disease, i.e. congestive heart failure, angina, arrhythmia requires a treatment, etc.
- •Subjects who have any history or complication of respiratory disease, i.e. bronchial asthma, chronic bronchitis, pneumonitis, etc. (except for a history of asthma in childhood)
- •Subjects who have any history or complication of gastrointestinal disease, i.e. peptic ulcer, reflux esophagitis, etc. (except for a history of appendicitis)
- •Subjects who have any history of gastrointestinal resection (except for a history of appendectomy)
- •Subjects who have any history or complication of renal disease, i.e. acute renal failure, glomerulonephritis, intestinal nephritis, etc.
- •Subjects who have any history or complication of endocrine disease, i.e. hyperthyroidism, abnormality of growth hormone, etc.
- •Subjects who have any history or complication of cerebrovascular disorder, i.e. cerebral infarction.
- •Subjects who have any history or complication of malignant tumor.
- •Subjects who have any history or complication of congenital short QT syndrome.
- •Subjects who have any history or complication of lymphatic disease, i.e. lymphoproliferative disease.
- •Subjects any of the following apply regarding tuberculosis:
- •History of active tuberculosis
- •Abnormality in chest X-ray test at screening
- •Contact with patients with infectious tuberculosis
- •Subjects any of the following apply regarding infectious disease other than tuberculosis:
- •History or complication of serious herpes zoster or disseminated herpes zoster
- •More than once relapse of localized herpes zoster
- •Hospitalization due to serious infection within 90 days before check-in in Period 1 (Day -1)
- •I.V. antibiotics treatment within 90 days before check-in in Period 1 (Day -1) (except for prevention use)
- •Judged as prone to infections by investigator or sub-investigator, i.e. subjects with urethral catheterization.
- •Subjects who have any history of inoculation of live vaccine or attenuated live vaccine within 56 days prior to check-in in Period 1 (Day -1).
- •Subjects who have any history of clinically serious allergy (Clinically serious allergy; allergy induced systemic urticaria or anaphylactic shock require hospitalization when exposed to specific antigens or drugs).
- •Subjects who have any history or complication of heart failure classified as NYHA Class III or IV.
- •Subjects who have a history of ASP015K administration.
- •Subjects with excessive alcohol drinking or smoking.
- •Criteria for "excessive":
- •Smoking: ≥ 20 cigarettes/day
- •Alcohol drinking: ≥ 45 g/day (a large bottle of beer contains 25 g of alcohol, 1 gou of Japanese sake contains 22 g of alcohol)
- •Employee of the sponsor, CROs or study site involved in this study.
- •Subjects judged as inappropriate for the study by investigator or sub-investigators.
研究组 & 干预措施
New Tablet Preceding Group
Experimental
Each subject received an ASP015K small tablet in period 1 and an ASP015K current tablet in period 2 under fasted conditions with 200 mL of water.
干预措施: peficitinib (Drug)
Current Tablet Preceding Group
Experimental
Each subject received an ASP015K current tablet in period 1 and an ASP015K small tablet in period 2 under fasted conditions with 200 mL of water.
干预措施: peficitinib (Drug)
结局指标
主要结局
Pharmacokinetics (PK) parameter of ASP015K: Area under the concentration-time curve (AUC) from the time of dosing to the time of the last sampling (AUCt)
时间窗: Up to 72 hours after each study drug dosing
Pharmacokinetics (PK) parameter of ASP015K: Maximum concentration (Cmax)
时间窗: Up to 72 hours after each study drug dosing
次要结局
- Pharmacokinetics (PK) profile of ASP015K: kel(Up to 72 hours after each study drug dosing)
- Pharmacokinetics (PK) profile of ASP015K: MRTinf(Up to 72 hours after each study drug dosing)
- Pharmacokinetics (PK) profile of ASP015K: t1/2(Up to 72 hours after each study drug dosing)
- Pharmacokinetics (PK) profile of ASP015K: tmax(Up to 72 hours after each study drug dosing)
- Safety assessed by 12-lead ECGs(Up to 6 days after the study drug dosing of Period 2)
- Pharmacokinetics (PK) profile of ASP015K: AUCinf(Up to 72 hours after each study drug dosing)
- Safety assessed by Adverse Events (AEs)(Up to 6 days after the study drug dosing of Period 2)
- Pharmacokinetics (PK) profile of ASP015K: AUClast(Up to 72 hours after each study drug dosing)
- Pharmacokinetics (PK) profile of ASP015K: CL/F(Up to 72 hours after each study drug dosing)
- Pharmacokinetics (PK) profile of ASP015K: Vz/F(Up to 72 hours after each study drug dosing)
- Safety assessed by Vital signs(Up to 6 days after the study drug dosing of Period 2)
- Safety assessed by Laboratory tests(Up to 6 days after the study drug dosing of Period 2)
研究者
相似试验
已完成
1 期
Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-RApetite StimulantsNCT06147908Daewon Pharmaceutical Co., Ltd.54
已完成
1 期
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid TumorsLung Cancer, Small CellNCT00259935GlaxoSmithKline107
已完成
1 期
A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy VolunteersHealthy VolunteerNCT01020136Pfizer42
已完成
1 期
Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg TabletsHealthyNCT01179646Kremers Urban Development Company48
已完成
1 期
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and FemaleHealthyNCT02266472Boehringer Ingelheim30